Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
Ridwanur Rahman(University of Dhaka), Bhawna Sharma(Drugs for Neglected Diseases Initiative), Manica Balasegaram(Global Antibiotic Research & Development Partnership), Margriet den Boer(Médecins Sans Frontières), Fabiana Alves(Drugs for Neglected Diseases Initiative), Sally Ellis(Drugs for Neglected Diseases Initiative), Vishal Goyal(Chandigarh University), Rasheda Samad(Chittagong Medical College), Suman Rijal(Nepal Cancer Hospital and Research Center), Rashidul Haque(International Centre for Diarrhoeal Disease Research), Kazi M. Jamil(International Centre for Diarrhoeal Disease Research), Jorge Alvar(Real Academia Española), Abul Faiz(Society of Toxicology), Nathalie Strub‐Wourgaft(Drugs for Neglected Diseases Initiative)
Cited by 78
Related Papers
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
|Clinical Microbiology Reviews|2018|218
Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis
|BMC Public Health|2017|72
AmBisome Monotherapy and Combination AmBisome–Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial
|Clinical Infectious Diseases|2022|53
An open source pharma roadmap
|PLoS Medicine|2017|52